Possibilties and shortcomings of maintenance therapy in gastroesophageal reflux disease

Digestive Surgery

Volumn 16, Issue 1, 1999, Pages 1-6

  Tytgat, G N J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antagonists; Gastroesophageal reflux disease; H2 receptor; Prokinetics; Proton pump inhibitors

Indexed keywords

CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR; PROTON PUMP;

ACID SECRETION; FOOD; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SURGERY; HUMAN; MAINTENANCE THERAPY; REBOUND; REMISSION; REVIEW; SYMPTOM; TACHYPHYLAXIS; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; LONG TERM CARE; MALE; PROGNOSIS; RECURRENT DISEASE; TREATMENT OUTCOME;

DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; LONG-TERM CARE; MALE; PROGNOSIS; PROTON PUMPS; RECURRENCE; TREATMENT OUTCOME;

EID: 0032587553     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000018685     Document Type: Review

References (20)

1. Tytgat GNJ: Long-term therapy for reflux esophagitis. N Engl J Med 1995:333:1148-1150.
2. Schoeman MN, Tippett MD, Akkermans LM, Dent J, Holloway RH: Mechanisms of gastroesophageal reflux in ambulant healthy human subjects. Gastroenterology 1995 108:83-91.
3. Mittal RK, Holloway RH, Penagini R, Blackshow LA, Dent J: Transient lower esophageal sphincter relaxation. Gastroenterology 1995; 109:601-610.
4. Mittal RK, Balaban DH: The esophagogastric junction. N Engl J Med 1997;336:924-932.
5. Hatlebakk JG, Berstad A: Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis. Scand J Gastroenterol 1996;31:954-958.
6. Tytgat GNJ, Janssens J, Reynolds JC, Wienbeck M: Update on the pathophysiology and management of gastro-oesophageal reflux disease: The role of prokinetic therapy. Eur J Gastroenterol Hepatol 1996;8:603-611.
7. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997;112: 1798-1810.
8. Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, Luckers A, Dekkers CP, Havu N, Meuwissen SG: Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety. Ann Intern Med 1994;121:161-167.
9. Leite LP, Johnston BT, Just RJ, Castell DO: Persistent acid secretion during omeprazole therapy: A study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996;91:1527-1531.
10. Hendel J, Hendel L, Hage E, Hendel J, Aggestrup S, Nielsen OH: Monitoring of omoprazole treatment in gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 1996;8:417-420.
11. Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L: Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drug: A meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997;11:473-482.
12. McDougall NI, Watson RGP, Collins JSA, McFarland RJ, Love AM: Maintenance therapy with cisapride after healing of erosive oesophagitis: A double-blind placebo-controlled trial. Aliment Pharmacol Ther 1997;11:487-495.
13. Hatlebakk JG, Johnsson F, Vilien M, Carling L, Wetterhus S, Thorgersen T: The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. Scand J Gastroenterol 1997;32:1100-1106.
14. Tytgat GNJ, Blum AL, Verlinden M: Prognostic factors for relapse and maintenance treatment with cisapride in gastroesophageal reflux disease. Aliment Pharmacol Ther 1995;9:271-280.
15. El-Omar E, Benerjee S, Wirz A, Penman I, Ardill JE, McColl KE: Marked rebound acid hypersecretion after treatment with ranitidine. Am J Gastroenterol 1996;91:355-359.
16. Hatlebakk JG, Berstad A: Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacolkinet 1996; 31:386-406.
17. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK: Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996;39:649-653.
18. Driman DK, Wright C, Tougas G, Riddell RH: Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Dig Dis Sci 1996; 41:2039-2047.
19. Heudebert GR, Marks R, Wilcox CM, Centor RM: Choice of long-term strategy for the management of patients with severe esophagitis: A cost-utility analysis. Gastroenterology 1997; 112:1078-1086.
20. Boeckxstaens GE, Hirsch DP, Fakhry N, Holloway RH, D'Amato M, Tytgat GN: Involvement of cholecystokinin-A receptors in transient lower oesophageal sphincter relaxations triggered by gastric distension. Am J Gastroenterol 1998;93:1823-1828.